NEOVACS SA NEOVACS ORD SHS (0W8U.L)

2.0000 +1.9972 (+71,328.88%) At close: 12:30PM BST

NEOVACS SA NEOVACS ORD SHS

3-5, Impasse Reille
Paris 75014
France

https://www.neovacs.com

Sector(s): 
Industry: 
Full-time employees: 23

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Hugo Brugiere M.Sc.	Chairman, GM & CEO	85k	N/A	N/A
Prof. Daniel Zagury	Founder, Chairman of Scientific Research Committee & Director	6k	N/A	N/A
Mr. Vincent Serra Ph.D.	Scientific & Operational Director	188.8k	N/A	1970
Mr. Alexandre Courtoux	Administrative & Financial Director	N/A	N/A	N/A
Charlene Masson	Corporate Communication & Investor Relations	N/A	N/A	N/A

Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of lupus erythematosus; and Phase IIa clinical trial for the treatment of dermatomyositis; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company was founded in 1993 and is based in Paris, France.

Corporate governance

NEOVACS SA NEOVACS ORD SHS’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.